REVIEW

In vitro-engineered non-antibody protein therapeutics

  • Rudo Simeon ,
  • Zhilei Chen
Expand
  • Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, TX 77845, USA

Received date: 05 Jan 2017

Accepted date: 13 Feb 2017

Published date: 01 Mar 2018

Copyright

2017 The Author(s) 2017. This article is published with open access at Springerlink.com and journal.hep.com.cn

Abstract

Antibodies have proved to be a valuable mode of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Unfortunately, antibodies are also limited in several respects, chief amongst those being the extremely high cost of manufacture. Therefore, non-antibody binding proteins have long been sought after as alternative therapies. New binding protein scaffolds are constantly being designed or discovered with some already approved for human use by the FDA. This review focuses on protein scaffolds that are either already being used in humans or are currently being evaluated in clinical trials. Although not all are expected to be approved, the significant benefits ensure that these molecules will continue to be investigated and developed as therapeutic alternatives to antibodies. Based on the location of the amino acids that mediate ligand binding, we place all the protein scaffolds under clinical development into two general categories: scaffolds with ligand-binding residues located in exposed flexible loops, and those with the binding residues located in protein secondary structures, such as α-helices. Scaffolds that fall under the first category include adnectins, anticalins, avimers, Fynomers, Kunitz domains, and knottins, while those belonging to the second category include affibodies, β-hairpin mimetics, and designed ankyrin repeat proteins (DARPins). Most of these scaffolds are thermostable and can be easily produced in microorganisms or completely synthesized chemically. In addition, many of these scaffolds derive from human proteins and thus possess very low immunogenic potential. Additional advantages and limitations of these protein scaffolds as therapeutics compared to antibodies will be discussed.

Cite this article

Rudo Simeon , Zhilei Chen . In vitro-engineered non-antibody protein therapeutics[J]. Protein & Cell, 2018 , 9(1) : 3 -14 . DOI: 10.1007/s13238-017-0386-6

1
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration. https://www.clinicaltrialsgov/ct2/show/study/NCT02181517.

2
Aboye TL, Stromstedt AA, Gunasekera S, Bruhn JG, El-Seedi H, Rosengren KJ, Goransson U (2015) A cactus-derived toxin-like cystine knot Peptide with selective antimicrobial activity. Chembiochem 16:1068–1077

3
Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581–589

4
Angelini A, Diderich P, Morales-Sanfrutos J, Thurnheer S, Hacker D, Menin L, Heinis C (2012) Chemical macrocyclization of peptides fused to antibody Fc fragments. Bioconjug Chem 23:1856–1863

5
Avrutina O (2016) Synthetic cystine-knot miniproteins—valuable scaffolds for polypeptide engineering. Adv Exp Med Biol 917:121–144

6
Bailon P, Won CY (2009) PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6:1–16

7
Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269–274

8
Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A (2003) Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 332:489–503

9
Bode W, Huber R (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433–451

10
Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557

11
Bork P (1993) Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins 17:363–374

12
Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 86:760–765

13
Caliceti P, Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Adv Drug Deliv Rev 55:1261–1277

14
Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT (2013) Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 155(697–704):e692

15
Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL (2006) Albumin binding to FcRn: distinct from the FcRn–IgG interaction. Biochemistry 45:4983–4990

16
Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281–298

17
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702–1712

18
Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523–531

19
Colgrave ML, Craik DJ (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43:5965–5975

20
Cooke MP, Perlmutter RM (1989) Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol 1:66–74

21
Craik DJ, Mylne JS, Daly NL (2010) Cyclotides: macrocyclic peptides with applications in drug design and agriculture. Cell Mol Life Sci 67:9–16

22
Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA (2016) Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 17:1102–1108

23
Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035–35043

24
Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA (2008) The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8:352

25
Dreier B, Pluckthun A (2011) Ribosome display: a technology for selecting and evolving proteins from large libraries. Methods Mol Biol 687:283–306

26
Dunlevy FK, Martin SL, de Courcey F, Elborn JS, Ennis M (2012) Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. J Cyst Fibros 11:300–304

27
Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7:9–14

28
Elsadek B, Kratz F (2012) Impact of albumin on drug delivery–new applications on the horizon. J Control Release 157:4–28

29
Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, Kurtz C (2010) Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 22:e312–e384

30
Fasan R, Dias RLA, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA (2004) Using a β-hairpin to mimic an α-helix: cyclic peptidomimetic inhibitors of the p53–HDM2 protein-protein interaction. Angew Chem Int Ed 43:2109–2112

31
Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JMW, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotech 21:163–170

32
Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Hoiden-Guthenberg I (2010) Design of an optimized scaffold for affibody molecules. J Mol Biol 398:232–247

33
Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular agerelated macular degeneration. Retina 26:859–870

34
Gai SA, Wittrup KD (2007) Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol 17:467–473

35
Gebauer M, Skerra A (2012) Anticalins small engineered binding proteins based on the lipocalin scaffold. Method Enzymol 503:157–188

36
Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L (2006) Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13:549–556

37
Gille H, Hulsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, Skerra A (2016) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. Angiogenesis 19:79–94

38
Grabulovski D, Kaspar M, Neri D (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 282:3196–3204

39
Gracy J, Le-Nguyen D, Gelly JC, Kaas Q, Heitz A, Chiche L (2008) KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids Res 36:D314–D319

40
Hackel BJ, Kapila A, Wittrup KD (2008) Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 381:1238–1252

41
Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21:283–288

42
Hosse RJ, Rothe A, Power BE (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15:14–27

43
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(33–38):27–38

44
Jost C, Pluckthun A (2014) Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 27:102–112

45
Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27:2322–2331

46
Kelley B (2009) Industrialization of mAb production technology the bioprocessing industry at a crossroads. mAbs 1:443–452

47
Kintzing JR, Cochran JR (2016a) Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr Opin Chem Biol 34:143–150

48
Kintzing JR, Cochran JR (2016b) Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr Opin Chem Biol 34:143–150

49
Kolmar H (2009) Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr Opin Pharmacol 9:608–614

50
Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22:868–876

51
Kristipati R, Nádasdi L, Tarczy-Hornoch K, Lau K, Miljanich GP, Ramachandran J, Bell JR (1994) Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels. Mol Cell Neurosci 5:219–228

52
Layer P, Stanghellini V (2014) Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 39:371–384

53
Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523–529

54
Lipovsek D (2011) Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 24:3–9

55
Lipovsek D, Pluckthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290:51–67

56
Madireddi M, Malone H, Kukral D, Chimalakonda A, Kozhich A, Xiling Y, Swain J, Yamniuk A, Ahlijanian M (2016) BMS-986089 is a high affinity anti-myostatin adnectin that increases muscle volume in three preclinical species. Neuromuscul Disord 26:S94–S95

57
Maillere B, Mourier G, Herve M, Cotton J, Leroy S, Menez A (1995) Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 33:475–482

58
Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D, Low S, Russo K, DiBella R, Denhez F (2014) Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 350:412–424

59
Moebius U, Feuerer W, Fenzl E, van Swelm R, Swinkels DW, Hohlbaum A (2015) A Phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects. Blood 126:536

60
Molecular Partners (2015). http://www.molecularpartners.com/preliminary-phase-i-results-demonstrate-potential-utility-of-darpinsin-anticancer-treatment/.

61
Moore SJ, Cochran JR (2012) Engineering knottins as novel binding agents. Methods Enzymol 503:223–251

62
Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, Gille H, Audoly LP, Scheulen ME (2013a) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 8: e83232

63
Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME (2013b) First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 8: e83232

64
Nguyen A, Reyes AE II, Zhang M, McDonald P, Wong WL, Damico LA, Dennis MS (2006) The pharmacokinetics of an albuminbinding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291–297

65
Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren P-A (1996) Binding proteins selected from combinatorial libraries of an [alpha]-helical bacterial receptor domain. Nat Biotech 15:772–777

66
Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15:772–777

67
Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. The Lancet 351:1693–1697

68
Nygren PA (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275:2668–2676

69
Paul L, Carlin E, Jenkins M (2016) Dengue virus antibodies enhance Zika virus infection. bioRxiv (http://www.biorxivorg/content/early/2016/04/25/050112).

70
Pieris Pharmaceuticals I (2015). http://www.pieris.com/newsand-events/press-releases/detail/524/pieris-pharmaceuticalspresents-clinical-data-for-its.

71
Pluckthun A (2015) Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol 55:489–511

72
Ramamurthy V, Krystek SR Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, Abramczyk B (2012) Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure 20:259–269

73
Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R (2006) A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag 31:393–406

74
Reichert JM (2017) Antibodies to watch in 2017. mAbs 9:167–181

75
Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ (2014) 9th Annual European antibody congress, November 11–13, 2013, Geneva, Switzerland. mAbs 6:309–326

76
Roberts BL, Markland W, Ley AC, Kent RB, White DW, Guterman SK, Ladner RC (1992) Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 89:2429–2433

77
Rodon J, Omlin A, Herbschleb KH, Garcia-Corbacho J, Steiner J, Dolado I, Zitt C, Feurstein D, Turner D, Dawson KM (2015) Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors. Mol Cancer Ther 14:B25

78
Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, Tolmachev V, Orlova A, Sorensen J, Carlsson J (2016) Biodistribution and radiation dosimetry of the Anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med 57:867–871

79
Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D (2015) Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investig New Drugs 33:247–253

80
Schilling J, Schoppe J, Pluckthun A (2014) From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J Mol Biol 426:691–721

81
Schlatter D, Brack S, Banner DW, Batey S, Benz J, Bertschinger J, Huber W, Joseph C, Rufer AC, van der Klooster A (2012) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. mAbs 4:497–508

82
Schmoldt HU, Wentzel A, Becker S, Kolmar H (2005) A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle. Protein Expr Purif 39:82–89

83
Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T (2007) Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120:416–422

84
Screaton G, Mongkolsapaya J, Yacoub S, Roberts C (2015) New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 15:745–759

85
Shah DK, Betts AM (2013) Antibody biodistribution coefficients. mAbs 5:297–305

86
Sidhu SS, Lowman HB, Cunningham BC, Wells JA (2000) Phage display for selection of novel binding peptides. Methods Enzymol 328:333–363

87
Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D (2014) Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem 289:14392–14398

88
Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs 8:141–149

89
Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556–1561

90
Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13:167–187

91
Skerra A (2008) Alternative binding proteins: anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 275:2677–2683

92
Smith HS, Deer TR (2009) Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 5:521–534

93
Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, West SM, Carrington B, Nesbitt A, Lawson AD, Antoniw P (2001) Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 12:750–756

94
Sorensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandstrom M, Lubberink M, Olofsson H (2016) Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT. Theranostics 6:262–271

95
Souied EH, Devin F, Mauget-Faÿsse M, Kolář P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S (2014a) Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 158(724–732):e722

96
Souied EH, Devin F, Mauget-Faysse M, Kolar P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S (2014b) Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 158(724–732):e722

97
Sparrow E, Friede M, Sheikh M, Torvaldsen S (2017) Therapeutic antibodies for infectious diseases. Bull World Health Org 95:1–81

98
Stein EA, Kasichayanula S, Turner T, Kranz T, Arumugam U, Biernat L, Lee J (2014) LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol 63:2889–2934

99
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480

100
Tam JP, Wang S, Wong KH, Tan WL (2015) Antimicrobial peptides from plants. Pharmaceuticals (Basel) 8:711–757

101
Thell K, Hellinger R, Sahin E, Michenthaler P, Gold-Binder M, Haider T, Kuttke M, Liutkeviciute Z, Goransson U, Grundemann C (2016) Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 113:3960–3965

102
Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363–371

103
Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–1458

104
Walker RG, Willingham AT, Zuker CS (2000) A Drosophila mechanosensory transduction channel. Science 287:2229–2234

105
Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, McGuire D, Ellis D, The Ziconotide Nonmalignant Pain Study, G. (2006) Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9:75–86

106
Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S (2000) Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 84:151–158

107
Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G (2013) The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genom Proteom 10:155–168

108
Werle M, Schmitz T, Huang H-L, Wentzel A, Kolmar H, Bernkop-Schnürch A (2006) The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 14:137–146

109
Williams A, Baird LG (2003) DX-88 and HAE: a developmental perspective. Transfus Apher Sci 29:255–258

110
Wong CT, Rowlands DK, Wong CH, Lo TW, Nguyen GK, Li HY, Tam JP (2012) Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed Engl 51:5620–5624

111
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T (2015) CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther 14:2473–2485

112
Zhu S, Darbon H, Dyason K, Verdonck F, Tytgat J (2003) Evolutionary origin of inhibitor cystine knot peptides. FASEB J 17:1765–1767

Outlines

/